Easing cisplatin's toll in nasopharyngeal carcinoma

Michael J Dennis; Ravindra Uppaluri

doi:10.1016/j.ccell.2025.03.034

Easing cisplatin's toll in nasopharyngeal carcinoma

Cancer Cell. 2025 May 12;43(5):814-816. doi: 10.1016/j.ccell.2025.03.034. Epub 2025 Apr 24.

Authors

Michael J Dennis¹, Ravindra Uppaluri²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: michael_dennis@dfci.harvard.edu.
² Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Division of Otolaryngology-Head and Neck Surgery, Brigham and Women's Hospital, Boston, MA, USA.

PMID: 40280122
DOI: 10.1016/j.ccell.2025.03.034

Abstract

Anti-PD-1 immune checkpoint inhibitors improve outcomes in relapsed/metastatic nasopharyngeal carcinoma (NPC). In this issue of Cancer Cell, Xu et al. achieved favorable outcomes by incorporating nivolumab into standard therapy for locally advanced NPC while removing chemotherapy from the radiation phase. This regimen offers a promising approach to reducing treatment-related toxicities.

MeSH terms

Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Cisplatin* / administration & dosage
Cisplatin* / therapeutic use
Humans
Immune Checkpoint Inhibitors / therapeutic use
Nasopharyngeal Carcinoma* / drug therapy
Nasopharyngeal Neoplasms* / drug therapy
Nasopharyngeal Neoplasms* / pathology
Nivolumab

Substances

Cisplatin
Immune Checkpoint Inhibitors
Nivolumab